Key result
Available evidence suggests that baseline functional class may largely explain the potentially harmful effects of GLP-1 receptor agonists in heart failure with reduced ejection fraction.
Why the study?
Does baseline NYHA functional class explain the effects of GLP-1RAs on heart failure outcomes in patients with HFrEF?
Does baseline NYHA functional class explain the effects of GLP-1RAs on heart failure outcomes in patients with HFrEF?
Answers are grounded in this paper and cite their sources.
This letter suggests that the potential harmful effects of GLP-1RAs in patients with HFrEF may be largely driven by those with advanced baseline symptoms (NYHA class III-IV), highlighting the need for further stratified research.
Ferreira and colleagues have given an updated view of glucagon-like peptide-1 receptor agonists (GLP-1RA) use in type 2 diabetes mellitus (T2DM) according to heart failure (HF) status (1). The authors must be congratulated for summarizing all the evidence; however, a few caveats need to be discussed further for future research. Our meta-analysis previously suggested a significant effect of baseline HF history on the effects of GLP-1RAs on the composite of hospitalizations due to HF (HHF) and cardiovascular death (CVD) in T2DM (P-interaction < .1) (2). Although their effects appeared to be neutral in people with prior HF (2), these effects on HHF/CVD in HF according to baseline ejection fraction (EF) or New York Heart Association (NYHA) functional class status could not be meta-analyzed due to lack of relevant data. The guidance to avoid GLP-1RA in HF with reduced EF (HFrEF) is presumably driven by a suggestion of increased risk of HHF with GLP-1RA use in the EXSCEL trial participants with a baseline EF of less than 40%. Notably, these effects were neutral in people with a diagnosis of HFrEF (odds ratio 1.49; 95% CI, 0.82-2.72) (3). Given the post hoc nature of the analysis, adequate characterization of the severity of these patients with baseline EF less than 40% was left unexplored, and conclusions were hypotheses-generating, as per the authors’ admission (3). Likewise, it remains uncertain whether the increased risk of serious cardiac adverse events in the LIVE trial participants with NYHA class I to III HFrEF was influenced by baseline HF severity according to NYHA class (4). In the FIGHT trial, the excess risk of HHF or death with GLP-1RA use was indeed limited only to HFrEF patients with NYHA class III to IV at baseline (hazard ratio, 1.86; 95% CI, 1.21-2.85 vs hazard ratio, 0.62; 95% CI, 0.31-1.23 in NYHA class I-II HF; P-interaction < .01) (5). Thus, this available evidence indicates that NYHA functional class at baseline may largely explain the harmful effects of GLP-1RAs in HFrEF.
No takes yet. Share an insight, caveat, or question.
Banerjee et al. (2023) conducted a letter in Type 2 diabetes mellitus and heart failure. Glucagon-like peptide-1 receptor agonists (GLP-1RA) was evaluated. Available evidence suggests that baseline functional class may largely explain the potentially harmful effects of GLP-1 receptor agonists in heart failure with reduced ejection fraction.
Synapse has enriched 10 related papers. Consider them for comparative context: